On Tuesday, 25 September 2018, Knowledge Ecology International delivered the following opening statement at the 2018 WIPO General Assembly. Opening Statement, Knowledge Ecology International KEI would like WIPO to continue work on, and evaluate the progress of, the obligation that… Continue Reading
On Thursday, 20 September 2018, Knowledge Ecology International (KEI) delivered the following statement in Rome during discussions at the WHO Regional Committee for Europe on the WHO Roadmap on Access to Medicines and Vaccines. Oral statement of Knowledge Ecology International… Continue Reading
The panel in a WTO dispute regarding Australia and plain packaging of tobacco products reached the conclusion that 2001 Doha Declaration on the TRIPS Agreement and Public Health has the status of an agreement that has modified the interpretation of… Continue Reading
On September 18, 2018, negotiations closed on what may be the final draft of the “Political Declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases.” The Declaration addresses the measures UN… Continue Reading
On Monday morning, 10 September 2018, Knowledge Ecology International (KEI) delivered the following oral statement at the World Health Organization’s (WHO) Informal Discussion of the Roadmap Report on Access to Medicines and Vaccines 2019–2023. The morning session provided UN agencies,… Continue Reading
On August 20, 2018, KEI filed comments in response to the US Federal Trade Commission’s hearings and public comment process to address, “Competition and Consumer Protection in the 21st Century.” The goal of the process is to examine, “whether broad-based… Continue Reading
On 12 June 2018 and 14 June 2018, the World Trade Organization (WTO) conducted a Trade Policy Review of Colombia. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place… Continue Reading
On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading
USTR has provided some details of the new trade agreement with Mexico, here. As usual, the agreement seems to favor drug companies and holders of copyrights, although few of the details are known. Among the specifics revealed are a proposed… Continue Reading
On August 20, 2018, KEI and T1International filed comments to the NIH regarding the prospective grant of an exclusive license to Inversago Pharma, a firm headquartered in Canada. According to the Federal Register notice 83 FR 38707, the NIH exclusive… Continue Reading